LVTX LAVA Therapeutics Company Short-Term Debt

lavatherapeutics.com - graphic logo of issuer LVTX

LAVA Therapeutics N.V. (LVTX) develops antibodies for the precise targeting of immune cells toward tumors, although the early stage of product development creates binary risks. The volume of short-term liabilities confirms the financial dynamics, where the 0.00 mark indicates the current debt level. The innovative cancer-fighting mechanism provides the company with high intellectual value when entering licensing deals with pharma behemoths.

LVTX Lava Tx Short-Term Debt (07/04/2022 - 12/06/2025)

Analytical breakdowns and data insights for company LAVA Therapeutics NV (LVTX)

- current quotes and average value forecast:
Price Chart Lava Tx|LVTX - Average Forecast Price
- market capitalization data:
Market Value LAVA Therapeutics N.V.|LVTX - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share LAVA Therapeutics|LVTX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio lavatherapeutics.com|LVTX - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio LAVA Therapeutics N.V.|LVTX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Lava Tx|LVTX - Aggregate Debt Obligations|Debts to Book Capitalization LAVA Therapeutics N.V.|LVTX - Long-Term Debt Volume|Company Short-Term Debt LAVA Therapeutics|Quick Liquidity lavatherapeutics.com
- earnings and multiples data:
LVTX - Net Income
General company analysis:lavatherapeutics.com (LVTX)
Flagship merchandise of LAVA Therapeutics N.V.

The issuer's reliability is determined by its ability to service obligations maturing within one year, which, in short-term debt statistics, reflects the balance between liquidity and investment potential. Reducing this burden minimizes default risk, allowing LAVA Therapeutics N.V. (LVTX) to allocate capital toward the development of high-precision gamma-delta T-cell cancer therapies for combating solid tumors without excessive financial pressure.

Competitors of LAVA Therapeutics N.V.

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IOVA|Immatics NV (IMTX) - Short-Term Indebtedness|Xencor Corp - Company Current Liabilities|Compass Therapeutics Corp (CMPX) - Short-Term Debt|REPL: Company Current Liabilities|Company Short-Term Loans and Borrowings LYEL (lyell.com)|IPHA: Company Short-Term Debts|PYXS - Short-Term Debt Volume|Company Short-Term Debt Compugen Ltd|Company Current Liabilities IO Biotech Inc. (IOBT)|Company Short-Term Debt Sutro Biopharma, Inc. (STRO)|Company Current Liabilities minktherapeutics.com INKT|Werewolf Therapeutics, Inc. - Company Current Liabilities|Company Short-Term Debts Immix Biopharma Inc. IMMX|ALXO - Company Short-Term Debt|CUE (Cue Biopharma Inc.) - Company Short-Term Indebtedness|pdsbiotech.com (PDSB) - Company Short-Term Debt|Short-Term Debt Sonnet BioTherapeutics Holdings (SONN)|Company Current Liabilities MAIA|LIMN - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)